First Fluorescence-Guided Ovarian Cancer Surgery

The first fluorescence-guided surgery on an ovarian cancer patient was performed using a cancer cell “homing device” and imaging agent created by a Purdue University researcher.

The surgery was one of 10 performed as part of the first phase of a clinical trial to evaluate a new technology to aid surgeons in the removal of malignant tissue from ovarian cancer patients. The method illuminates cancer cells to help surgeons identify and remove smaller tumors that could otherwise be missed.

Philip Low, the Ralph C. Corely Distinguished Professor of Chemistry who invented the technology, said surgeons were able to see clusters of cancer cells as small as one-tenth of a millimeter, as opposed to the earlier average minimal cluster size of 3 millimeters in diameter based on current methods of visual and tactile detection.

“Ovarian cancer is notoriously difficult to see, and this technique allowed surgeons to spot a tumor 30 times smaller than the smallest they could detect using standard techniques,” Low said. “By dramatically improving the detection of the cancer — by literally lighting it up — cancer removal is dramatically improved.”

The technique attaches a fluorescent imaging agent to a modified form of the vitamin folic acid, which acts as a “homing device” to seek out and attach to ovarian cancer cells. Patients are injected with the combination two hours prior to surgery and a special camera system, called a multispectral fluorescence camera, then illuminates the cancer cells and displays their location on a flat-screen monitor next to the patient during surgery.

The surgeons involved in this study reported finding an average of 34 tumor deposits using this technique, compared with an average of seven tumor deposits using visual and tactile observations alone. A paper detailing the study was published online in Nature Medicine.

Gooitzen van Dam, a professor and surgeon at the University of Groningen in The Netherlands where the surgeries took place, said the imaging system fits in well with current surgical practice.

“This system is very easy to use and fits seamlessly in the way surgeons do open and laparoscopic surgery, which is the direction most surgeries are headed in the future,” said van Dam, who is a surgeon in the division of surgical oncology and Bio-Optical Imaging Center at the University of Groningen. “I think this technology will revolutionize surgical vision. I foresee it becoming a new standard in cancer surgery in a very short time.”

Research has shown that the less cancerous tissue that remains, the easier it is for chemotherapy or immunotherapy to work, Low said.

“With ovarian cancer it is clear that the more cancer you can remove, the better the prognosis for the patient,” he said. “This is why we chose to begin with ovarian cancer. It seemed like the best place to start to make a difference in people’s lives.”

By focusing on removal of malignant tissue as opposed to evaluating patient outcome, Low dramatically reduced the amount of time the clinical trial would take to complete.

“What we are really after is a better outcome for patients, but if we had instead designed the clinical trial to evaluate the impact of fluorescence-guided surgery on life expectancy, we would have had to follow patients for years and years,” he said. “By instead evaluating if we can identify and remove more malignant tissue with the aid of fluorescence imaging, we are able to quantify the impact of this novel approach within two hours after surgery. We hope this will allow the technology to be approved for general use in a much shorter time.”

Low and his team are now making arrangements to work with the Mayo Clinic for the next phase of clinical trials.

The technology is based on Low’s discovery that folic acid, or folate, can be used like a Trojan horse to sneak an imaging agent or drug into a cancer cell. Most ovarian cancer cells require large amounts of the vitamin to grow and divide, and special receptors on the cell’s surface grab the vitamin — and whatever is linked to it — and pull it inside. Not all cancer cells express the folate receptor, and a simple test is necessary to determine if a specific patient’s cancer expresses the receptor in large enough quantities for the technique to work, he said.

Ovarian cancer has one of the highest rates of folate receptor expression at about 85 percent. Approximately 80 percent of endometrial, lung and kidney cancers, and 50 percent of breast and colon cancers also express the receptor, he said.

Low also is investigating targeting molecules that could be used to carry attached imaging agents or drugs to forms of cancer that do not have folate receptors.

He next plans to develop a red fluorescent imaging agent that can be seen through the skin and deep into the body. The current agent uses a green dye that had already been through the approval process to be used in patients, but cannot easily be seen when present deep in tissue. Green light uses a relatively short wavelength that limits its ability to pass through the body, whereas the longer wavelengths of a red fluorescent dye can easily be seen through tissue.

“We want to be able to see deeper into the tissue, beyond the surface,” Low said. “Different cancers have tumors with different characteristics, and some branch and wind their way deeper into tissue. We will continue to evolve this technology and make improvements that help cancer patients.”

In addition to Low and van Dam, the paper’s authors include George Themelis, Athanasios Sarantopoulos and Vasilis Ntziachristos of the Institute for Biological and Medical Imaging at the Technical University of Munich in Germany; Lucia Crane, Niels Harlaar, Rick Pleijhuis, Wendy Kelder and Johannes de Jong of the division of surgical oncology of the BioOptical Imaging Center at the University of Groningen; Henriette Arts and Ate van der Zee of the division of gynaecological oncology at the University of Groningen; and Joost Bart of the Department of Pathology and Molecular Biology of the University Medical Center of Groningen.

Low is the chief science officer for Endocyte Inc., a Purdue Research Park-based company that develops receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. Endocyte holds the license to the folate receptor-targeting technology and is spinning this technology off into a new company called OnTarget.

Ntziachristos led the team at the Technical University of Munich that developed the camera system. A startup company named SurgOptix BV is working to commercialize the camera system.

The clinical trial was funded by Endocyte Inc. and the University Medical Center of Groningen.

Read more here 

Share

Posted: September 19th, 2011 under Uncategorized.

RSS Medical Imaging News

  • FDG-PET/CT shows promise for breast cancer patients younger than 40 October 1, 2014
    PET/CT imaging of patients younger than 40 who were initially diagnosed with stage I–III breast cancer resulted in change of diagnosis, a study shows. While guidelines recommend FDG-PET/CT imaging only for women with stage III breast cancer, it can also help physicians more accurately diagnose young breast cancer patients initially diagnosed with earlier sta […]
  • 'Virtual breast' could improve cancer detection September 30, 2014
    A 'virtual breast' has been developed to help train clinicians in the use of ultrasound elastography. The advanced imaging technique holds promise for improving cancer detection, but only if the results are interpreted properly.
  • Safer approach for diagnostic medical imaging September 29, 2014
    A novel approach that can considerably improve the capabilities of medical imaging with safer procedures for the patient has been developed by researchers.
  • Customizing chemotherapy in lung cancer: New phase II data reported September 27, 2014
    Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown. In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment wit […]
  • Cryptogenic strokes may find explanation in heart September 25, 2014
    More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin.
  • Study questions accuracy of lung cancer screens with FDG-PET technology in some geographic regions September 23, 2014
    FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common, a new study suggests. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality.
  • Patients accept false-positives to achieve diagnostic sensitivity September 23, 2014
    Both patients and healthcare professionals believe diagnosis of extracolonic malignancy with screening computed tomography colonography greatly outweighs the potential disadvantages of subsequent radiologic or invasive follow-up tests precipitated by false-positive diagnoses, according to a new study.
  • Fine line between breast cancer, normal tissues September 22, 2014
    A tool has been successfully tested that will help surgeons better distinguish cancerous breast tissue from normal tissue, thereby decreasing the chances for repeat operations. The tool, known as DESI mass spectrometry imaging, works by turning molecules into electrically charged versions of themselves, called ions, so that they can be identified by their ma […]
  • Research on photoacoustics to detect breast cancer September 22, 2014
    Researchers report a new method to detect breast cancer based on photoacoustics, which could become an alternative to mammography or sonogram, they say. One advantage this method has over X-rays is that no type of ionizing radiation is used. This technology exploits the property of ultrasonic wave generation in tissue when it is illuminated with short, high- […]
  • Ultrasound enhancement provides clarity to damaged tendons, ligaments September 19, 2014
    Ultrasound is a safe, affordable and noninvasive way to see internal structures, including the developing fetus. Ultrasound can also “see” other soft tissue — including tendons, which attach muscles to bone, and ligaments, which attach bone to bone. Now one expert is commercializing an ultrasound method to analyze the condition of soft tissue.

News Items

Links